GDF2 and pulmonary arterial hypertension: BMP9 has been described as the preferred ligand for preventing apoptosis and enhancing monolayer integrity in ECFC from patients with BMPRII mutations (40), and has been used to reverse established PAH in preclinical models, suggesting new potential therapeutic approaches for inherited PAH.